| Literature DB >> 31115326 |
Damien Cohen1, Yusuke Shimakawa2, Gibril Ndow3, Amina Sow3, Saydiba Tamba3, Ramou Njie4, Gora Lo5, Sumantra Ghosh1, Coumba Toure-Kane3, Mourtalla Ka5, Souleymane Mboup5, Edith Okeke6, Souleymane Toure5, Madoky Diop5, Umberto D'Alessandro7, Simon Taylor-Robinson3, Maimuna Mendy7, Fabien Zoulim1, Mark R Thursz3, Maud Lemoine3, Isabelle Chemin1.
Abstract
Despite the existence of an effective vaccine, HBV infects 257 million people worldwide and is the cause of the majority of HCC. With an annual mortality rate of 887 000 patients in 2015, this cancer is the second deadliest. Low-income countries such as ones in sub-Saharan Africa are the most at risk due to the limited access to healthcare. To overcome this and born from an international research collaboration within an EU project, the Prolifica study aimed at evaluating a screen-and-treat program to prevent HBV complications, and more particularly HCC. Based on communities, facilities and hospitals HBsAg+ detection, the study lasted from 2011 to 2016. From the "cost effectiveness" feasibility of such a program to the development of simple scores for antiviral treatment, Prolifica uncovered data of crucial importance in a region with low HBV infection awareness, transmissions modes and prevention means which could have impacts on public health policies.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31115326 DOI： 10.1051/medsci/2019076
Source DB: PubMed Journal: Med Sci (Paris) ISSN： 0767-0974 Impact factor: 0.818